Canopus Biopharma Incorporated Stock Buy Hold or Sell Recommendation
| CBIA Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Canopus BioPharma Incorporated is 'Sell'. Macroaxis provides Canopus BioPharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CBIA positions.
Check out Canopus BioPharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Canopus and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Canopus BioPharma Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Canopus |
Execute Canopus BioPharma Buy or Sell Advice
The Canopus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Canopus BioPharma Incorporated. Macroaxis does not own or have any residual interests in Canopus BioPharma Incorporated or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Canopus BioPharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Canopus BioPharma Trading Alerts and Improvement Suggestions
| Canopus BioPharma is way too risky over 90 days horizon | |
| Canopus BioPharma has some characteristics of a very speculative penny stock | |
| Canopus BioPharma appears to be risky and price may revert if volatility continues |
Canopus BioPharma Returns Distribution Density
The distribution of Canopus BioPharma's historical returns is an attempt to chart the uncertainty of Canopus BioPharma's future price movements. The chart of the probability distribution of Canopus BioPharma daily returns describes the distribution of returns around its average expected value. We use Canopus BioPharma Incorporated price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Canopus BioPharma returns is essential to provide solid investment advice for Canopus BioPharma.
| Mean Return | 6.82 | Value At Risk | -50 | Potential Upside | 100.00 | Standard Deviation | 41.03 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Canopus BioPharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Canopus BioPharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Canopus BioPharma or Financial Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Canopus BioPharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Canopus pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 6.90 | |
β | Beta against Dow Jones | 6.12 | |
σ | Overall volatility | 38.73 | |
Ir | Information ratio | 0.17 |
Canopus BioPharma Volatility Alert
Canopus BioPharma Incorporated is showing large volatility of returns over the selected time horizon. Canopus BioPharma Incorporated appears to be a penny stock. Although Canopus BioPharma Incorporated may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Canopus BioPharma Incorporated or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Canopus instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Canopus BioPharma Fundamentals Vs Peers
Comparing Canopus BioPharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Canopus BioPharma's direct or indirect competition across all of the common fundamentals between Canopus BioPharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Canopus BioPharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Canopus BioPharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Canopus BioPharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Canopus BioPharma to competition |
| Fundamentals | Canopus BioPharma | Peer Average |
| Shares Outstanding | 9.3 M | 571.82 M |
| Net Income | 1.68 M | 570.98 M |
| Cash Flow From Operations | 1.98 M | 971.22 M |
| Number Of Employees | 4 | 18.84 K |
| Beta | -2.23 | -0.15 |
| Market Capitalization | 364.56 K | 19.03 B |
| Total Asset | 1.56 M | 29.47 B |
| Retained Earnings | (10.29 M) | 9.33 B |
| Current Asset | 92 K | 9.34 B |
| Current Liabilities | 2.36 M | 7.9 B |
| Z Score | -8.4 | 8.72 |
| Net Asset | 1.56 M |
Canopus BioPharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Canopus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 | |||
| Relative Strength Index | 48.01 |
About Canopus BioPharma Buy or Sell Advice
When is the right time to buy or sell Canopus BioPharma Incorporated? Buying financial instruments such as Canopus Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Canopus BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sport Products Thematic Idea Now
Sport Products
Companies manufacturing sporting goods and accessories. The Sport Products theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Canopus Pink Sheet
Canopus BioPharma financial ratios help investors to determine whether Canopus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canopus with respect to the benefits of owning Canopus BioPharma security.